● pepmg Research Desk · Peer-reviewed evidence review
What the research says about LL-37
A neutral summary of the peer-reviewed literature on LL-37, the only human cathelicidin antimicrobial peptide, studied largely as native host-defense biology and in preclinical models, with context-dependent and sometimes harmful effects. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- LL-37 is the only human cathelicidin, an antimicrobial and immunomodulatory peptide released from the hCAP18 precursor protein as part of innate host defense in skin, gut, and airways [1][4].
- Most of the literature studies LL-37's native biology and its potential as a future therapeutic in cell and animal models; no controlled human trials of administered LL-37 appear in this corpus [2][6][7].
- Its effects are context-dependent and double-edged: the same peptide can defend against infection and promote tissue repair, yet is also implicated in inflammatory disease and shows opposite (tumor-promoting and tumor-inhibiting) effects depending on tissue [4][9].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What LL-37 is
LL-37 is the only member of the cathelicidin family of host-defense peptides expressed in humans. It is proteolytically released from the C-terminal end of the human cathelicidin precursor protein hCAP18, and is produced mainly by phagocytic white blood cells and by epithelial cells lining barrier organs such as the gut, airways, and skin [3][5]. As part of innate immunity, it acts as a broad-spectrum antimicrobial and as a signaling molecule with chemotactic and immunomodulatory roles [2][3].
This is an important distinction from most peptides in this library: LL-37 is primarily an endogenous molecule, and the bulk of research studies the body's own peptide rather than an injected drug. Material sold by research-chemical vendors is a synthetic version offered for laboratory and research use only; it is not an approved medicine.
What the research has measured
Preclinical onlyThe best-characterized activity is antimicrobial and immunomodulatory. Reviews describe LL-37 as a potent killer of bacteria and fungi that also disrupts bacterial biofilms, neutralizes bacterial lipopolysaccharide to protect against lethal endotoxemia, and has antiviral and antiparasitic properties, while additionally acting as a chemoattractant and stimulating angiogenesis and tissue regeneration [1][3]. Its therapeutic potential has been discussed across immunological, respiratory, gastrointestinal, and skin systems [2].
Direct experiments are preclinical. In a murine cecal-ligation-and-puncture model of sepsis, LL-37 was tested for effects on the inflammatory response [7]. A full-thickness wound-closure study examined whether LL-37 accelerates healing; although the record is indexed as "human," the experiment was performed in diabetic mice to probe an autophagy-dependent mechanism, not in patients [6]. Because there has been growing interest in improving on the natural molecule, much recent work designs engineered LL-37-derived peptides rather than testing LL-37 itself [8][9].
The corpus contains no randomized or otherwise controlled clinical trials of administering LL-37 to people. The human question, whether giving LL-37 as a drug helps any condition, is essentially unaddressed by trial evidence here.
What the studies report on safety and adverse events
Preclinical onlyThe most important honesty point about LL-37 is that it is not uniformly beneficial. Reviews emphasize a double-edged, context-dependent character: in cancer biology, the accumulated evidence shows LL-37 can have two different and contradictory effects, either promoting or inhibiting tumor growth depending on the tissue and receptor context [4]. LL-37 is also implicated in the pathophysiology of inflammatory conditions rather than only defending against them, and its roles in cardiovascular processes such as atherosclerosis and thrombosis are described as complex [9].
Because the research is preclinical and much of it concerns the endogenous peptide, there is no controlled human safety database here for administered LL-37. That absence, combined with the peptide's documented capacity for both helpful and harmful effects, means nothing here should be read as reassurance about exogenous use. Material sold by research-chemical vendors is not an approved product and has not undergone human safety testing. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence is characterized as preclinical. LL-37 is one of the most intensively studied human antimicrobial peptides, but that research is overwhelmingly about its native biology and about cell and animal models of potential therapeutic use [1][2][7]; controlled human trials of LL-37 as an administered compound are absent from this corpus. "Preclinical" describes the stage and setting of the work, not a verdict. Given the peptide's documented double-edged effects, the preclinical label should be read as a genuine open question, not as latent promise [4][9].
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 9
- Unique features of human cathelicidin LL-37.
- LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity.
- Cathelicidin LL-37: a multitask antimicrobial peptide.
- The Role of Cathelicidin LL-37 in Cancer Development.
- The Roles of Cathelicidin LL-37 in Inflammatory Bowel Disease.
- Cathelicidin LL-37 promotes wound healing in diabetic mice by regulating autophagy.
- Therapeutic Potential of Cathelicidin Peptide LL-37 in a murine sepsis model.
- Design of Antimicrobial Peptides: Progress Made with Human Cathelicidin LL-37.
- Cathelicidin peptide LL-37: A multifunctional peptide involved in heart disease.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.